Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27551847 | 0.84 | CA1 (0.36) | KDM4EALDH1A1TDP1NR4A3KMT2A | |
| SCHEMBL18209761 | 0.81 | MCL1 (0.37) | KDM4EALDH1A1LMNATDP1NR4A3 | |
| SCHEMBL18209696 | 0.81 | KDM4E (0.34) | KDM4EALDH1A1TDP1NR4A3SMN1; SMN2 | |
| SCHEMBL2360995 | 0.77 | NPC1 (0.45) | KDM4EALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL10718645 | 0.76 | NOTUM (0.41) | LMNAMAPK1NR4A3SMN1; SMN2NPC1 | |
| SCHEMBL7722135 | 0.72 | KDM4E (0.41) | KDM4EALDH1A1TDP1NR4A3SMN1; SMN2 | |
| SCHEMBL966692 | 0.72 | KDM4E (0.41) | KDM4EALDH1A1TDP1NR4A3SMN1; SMN2 | |
| SCHEMBL1663553 | 0.72 | SMN1; SMN2 (0.50) | KDM4EALDH1A1LMNAMAPK1TDP1 | |
| SCHEMBL68535 | 0.72 | PDE10A (0.41) | KDM4EALDH1A1TDP1NR4A3SMN1; SMN2 | |
| SCHEMBL7023904 | 0.72 | NR4A3 (0.30) | NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739685-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008061-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| CN-102216285-B | Tetrasubstituted pyridazine hedgehog pathway antagonists | LILLY CO ELI | 2014-08-13 | — | — | CN | disclosed |
| US-8507490-B2 | Tetrasubstituted pyridazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507490-B2 | Tetrasubstituted pyridazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507490-B2 | Tetrasubstituted pyridazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2358698-B1 | TETRASUBSTITUTED PYRIDAZINE AS HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110263602-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263602-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263602-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
| CN-102216285-A | Tetrasubstituted pyridazine hedgehog pathway antagonists | LILLY CO ELI | 2011-10-12 | — | — | CN | disclosed |
| EP-2358698-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | Eli Lilly and Company (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010056588-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056588-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263602-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, SMO, GLI1 | KDM4E 702/4885ALDH1A1 4107/4885LMNA 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.